Score Overview
Explore the 2021 public Archive ranking →
Where BioCryst Pharmaceuticals Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- BCRX
1999: 23.5% · 2021: 89.4% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 8.27 | — |
1 Year2025-09-29 | $ 7.55 | 9.54% |
5 Years2021-09-29 | $ 14.38 | -42.49% |
10 Years2016-09-29 | $ 4.45 | 85.84% |
20 Years2006-09-29 | $ 12.47 | -33.68% |
30 Years1996-09-27 | $ 12.38 | -33.17% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | 30 Years1996-09-27 |
|---|---|---|---|---|---|---|
| Price | $ 8.27 | $ 7.55 | $ 14.38 | $ 4.45 | $ 12.47 | $ 12.38 |
| Return | — | 9.54% | -42.49% | 85.84% | -33.68% | -33.17% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 940M | -$ 384M | $ 352M |
| 2025 | $ 874M | $ 263M | $ 274M |
| 2024 | $ 450M | -$ 88M | $ 321M |
| 2023 | $ 331M | -$ 226M | $ 388M |
| 2022 | $ 270M | -$ 247M | $ 424M |
| 2021 | $ 157M | -$ 184M | $ 507M |
| 2020 | $ 17M | -$ 182M | $ 300M |
| 2019 | $ 48M | -$ 108M | $ 136M |
| 2018 | $ 20M | -$ 101M | $ 126M |
| 2017 | $ 25M | -$ 65M | $ 155M |
| 2016 | $ 26M | -$ 55M | $ 63M |
| 2015 | $ 48M | -$ 43M | $ 99M |
| 2014 | $ 13M | -$ 45M | $ 113M |
| 2013 | $ 17M | -$ 30M | $ 40M |
| 2012 | $ 26M | -$ 39M | $ 36M |
| 2011 | $ 19M | -$ 56M | $ 41M |
| 2010 | $ 63M | -$ 32M | $ 53M |
| 2009 | $ 74M | -$ 13M | $ 68M |
| 2008 | $ 56M | -$ 24M | $ 61M |
| 2007 | $ 71M | -$ 29M | $ 50M |
| 2006 | $ 6M | -$ 43M | $ 37M |
| 2005 | $ 151.87K | -$ 26M | $ 50M |
| 2004 | $ 336.9K | -$ 21M | $ 23M |
| 2003 | $ 1M | -$ 12M | $ 20M |
| 2002 | $ 1M | -$ 16M | $ 24M |
| 2001 | $ 11M | -$ 4M | $ 31M |
| 2000 | $ 3M | -$ 11M | $ 24M |
| 1999 | $ 2M | -$ 5M | $ 23M |
| 1998 | $ 6M | -$ 4M | $ 12M |
| 1997 | $ 1M | -$ 10M | $ 3M |
| 1996 | $ 2M | -$ 7M | $ 3M |
| 1995 | $ 200K | -$ 8M | $ 6M |
| IPO1994 | $ 700K | -$ 6M | $ 2M |
BioCryst Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 17M to $ 874M and net income went from -$ 182M to $ 263M. Revenue increased in every one of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 48M to $ 874M and net income went from -$ 43M to $ 263M. Revenue increased in 7 of those 10 years; net income in 3.
BioCryst Pharmaceuticals Inc currently holds a 20-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.
Membership
Continue BCRX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
